ALK and non-small cell lung carcinoma: Adding further evidence to the clinical utility of this approach, in a retrospective analysis on NSCLC plasma samples using the Guardant360 NGS gene panel, 11/42 (26%) patients whose tissue biopsy was inadequate for analysis were found positive for ALK rearrangement in cfDNA.